US pharmaceutical sales growth could slow by almost 1% for 2006, due to the launch of a generic version of clopidogrel [Plavix]

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.513, 2006-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The US FDA has granted the generics company Teva approval to launch a generic version of amoxicillin/clavulanic acid

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 389, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Mexico leads global pharmaceutical sales growth

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 331, 2001-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

The growth of the global pharmaceutical market is expected to slow in 2008

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 541, 2007-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Factors driving US drug sales growth

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 313, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Teva Pharmaceutical Industries has decided not to sell generic Lipitor [atorvastatin] in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 655, 2012-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite